OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gerson on Strategies Aimed at Alleviating Toxicity in Older Patients With MCL

October 15th 2019

James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, discusses strategies aimed at alleviating toxicity in older patients with mantle cell lymphoma (MCL).

Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma

October 15th 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the CheckMate-204 trial in melanoma.

Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

October 15th 2019

Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Dr. Giri on Increasing Awareness of Genetic Testing in Prostate Cancer

October 15th 2019

Veda N. Giri, MD, discusses the increasing need for genetic counseling among men at risk of developing prostate cancer.

Dr. Coleman on Rationale for Using Veliparib and Chemotherapy in Ovarian Cancer

October 15th 2019

Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.

Dr. Waxman on the Role of Transplant in Multiple Myeloma

October 14th 2019

Adam J. Waxman, MD, MS, discusses the role of transplant in patients with multiple myeloma.

Dr. Wierda on Role of Rituximab Biosimilar in Evolving CLL Treatment Paradigm

October 14th 2019

William G. Wierda, MD, PhD, discusses the role of the rituximab biosimilar in the chronic lymphocytic leukemia treatment paradigm.

Dr. Zhang on the IMvigor130 Trial in Metastatic Urothelial Cancer

October 12th 2019

Tian Zhang, MD, discusses data from the randomized phase III IMvigor130 trial, which compared the safety and efficacy of atezolizumab in combination with platinum-based chemotherapy, atezolizumab monotherapy, and chemotherapy alone, in the frontline treatment of patients with metastatic urothelial cancer.

Dr. Kim on the KEYNOTE-189 Trial in Metastatic NSCLC

October 12th 2019

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.

Dr. Long on Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

October 12th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the long-term data from the phase II ABC study , in which investigators are comparing the efficacy of nivolumab in combination with ipilimumab versus single-agent nivolumab in patients with melanoma brain metastases.

Dr. Mesa on Ruxolitinib Vs Fedratinib in Myelofibrosis Treatment

October 12th 2019

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck CSCC

October 12th 2019

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.

Dr. Bekaii-Saab on Safety Profile of Tucatinib/Trastuzumab in HER2-Amplified mCRC

October 11th 2019

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.

Potential Molecular Markers in Liver Cancer

October 11th 2019

Anuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.

Dr. O'Reilly on the NEOLAP Study in Locally Advanced Pancreatic Cancer

October 11th 2019

Eileen O'Reilly, MD, discusses the phase II NEOLAP study which showed that more patients with locally advanced pancreatic cancer were able to undergo surgical resection following induction chemotherapy with gemcitabine and nab-paclitaxel or sequential FOLFIRINOX.

Dr. Hussain on Results of the PROfound Trial in mCRPC

October 11th 2019

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Feinberg School of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the results of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Marcom on Liquid Biopsies in Breast Cancer

October 11th 2019

Paul Kelly Marcom, MD, discusses the use of liquid biopsies in breast cancer treatment.

Dr. Saba Discusses Ongoing Research in Head and Neck Cancer

October 11th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.

Dr. Shah on CAR T-Cell Therapy in Pediatric ALL

October 10th 2019

Nirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.

Dr. Bourhis on Results of the Phase II Trial With Debio 1143 in Head and Neck Cancer

October 10th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the results of a phase II trial evaluating the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.